Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Primary Care

Journal Scan / Research · June 02, 2022

Amitriptyline vs Pregabalin, Duloxetine, and Milnacipran for Fibromyalgia

JAMA Network Open

 

Additional Info

Disclosure statements are available on the authors' profiles:

JAMA Network Open
Comparison of Amitriptyline and US Food and Drug Administration-Approved Treatments for Fibromyalgia: A Systematic Review and Network Meta-analysis
JAMA Netw Open 2022 May 02;5(5)e2212939, HM Farag, I Yunusa, H Goswami, I Sultan, JA Doucette, T Eguale

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading